Molecular Signal Analysis
Blood-first molecular signal analysis for early pancreatic cancer detection.
Genoll is developing a science-led diagnostic approach to identify pancreatic cancer-related molecular signals earlier and support clinician-reviewable insights through multi-omics analysis and machine learning.
The Challenge
Pancreatic cancer is detected too late.
Pancreatic cancer is often found after symptoms appear and clinical options narrow. Genoll is focused on the earlier diagnostic window, where molecular changes may already be present before conventional suspicion is triggered.
Status Quo
Late clinical presentation
Current tools usually enter after suspicion is raised, limiting treatment avenues.
Early Window
Subtle early signals
Molecular changes may exist at trace levels before symptoms become clinically obvious.
Objective
Need for earlier review
Earlier signal detection can support timely clinician-led confirmatory workup, which can change patient outcomes.
Methodology
A science-led molecular diagnostic approach.
Genoll is developing a blood-based approach that evaluates molecular signals across multiple biological layers. The approach combines multi-omics molecular evaluation and machine learning-assisted signal interpretation.
Liquid Biopsy
Designed around a standard, non-invasive venous blood draw that fits easily into existing outpatient oncology workflows.
Multi-omics Core Engine
Transcriptomic expression signatures and genomic context combined to read tumor biology and isolate crucial biomarkers.
Machine Learning Prediction
Advanced ML models process complex multi-omics data to accurately predict and classify early-stage disease signatures.
Clinician-Reviewable Insight
Structured reports designed to deliver actionable clinical insights directly to oncology specialists.
Collaborate